Following their discovery at the end of the 20th century, extracellular vesicles (EVs) ranging
from 50-1,000 nm have proven to be paramount in the progression of many cancers …

Targeted therapy with Bruton tyrosine kinase (BTK) inhibitors have revolutionized the
treatment of patients with various B-cell malignancies. BTK inhibitors such as ibrutinib …

Simple Summary The treatment landscape for CLL has changed dramatically since the
advent of targeted therapies. Studies have shown clear progression-free survival (PFS) …

Chronic lymphocytic leukaemia (CLL) is a malignancy of clonally expanded antigen-
switched, neoplastic, mature B cells. CLL is characterised by a variable degree of …

Chronic lymphocytic leukemia (CLL), is a hematologic malignancy characterized by the
uncontrolled proliferation of mature B lymphocytes. CLL is the most prevalent leukemia in …

Galectin-3's (Gal-3) effect on the pathogenesis of chronic lymphocytic leukemia (CLL) has
not yet been extensively studied. The present study aims to analyze the potential role of Gal …

Simple Summary Recent advances in treating elderly patients with chronic lymphocytic
leukemia (CLL) have emphasized the importance of geriatric assessment (GA) to evaluate …

Simple Summary Since the identification of a large variety of biomarkers in B cell
malignancies as being driving factors for tumor progression and patient prognosis, their …

Simple Summary Aquaporins are proteins able to regulate the transfer of water and other
small substances such as ions, glycerol, urea, and hydrogen peroxide across cellular …

Small‐molecule inhibitors have revolutionized the treatment of chronic lymphocytic leukemia
(CLL), a landscape once dominated by chemoimmunotherapy (ie, an anti‐CD20 …